Immunovant

There is potential for anti-neonatal Fc receptor (anti-FcRn) technology to help a broad range of people impacted by autoimmune diseases. Over 2 million people are estimated to be living with conditions mediated by harmful immunoglobulin G (IgG) autoantibodies.

Immunovant’s mission centers on improving lives for people with autoimmune diseases by addressing individual patient needs.

The company relies on volunteers to advance clinical trials for autoimmune disease therapies.

Immunovant’s proof-of-concept study of IMVT-1402 in cutaneous lupus erythematosus did not meet statistical significance.

IMVT-1402 600 mg demonstrated a 92.5% ACR20 response rate at Week 28 compared to 75.6% for placebo in Period 2.

Immunovant warns about fraudulent communications claiming false job offers or interviews.

Immunovant prioritizes innovation and inclusivity to accelerate therapies for autoimmune diseases.

Jake Bauer, MBA, has served as a member of our Board of Directors since April 2025. Mr. Bauer has served as a Venture Partner at ARCH Venture Partners and SR One Capital Management since September 2021 and as an independent consultant working with companies in the life sciences industry since November 2020. Prior to MyoKardia, Inc.’s acquisition by Bristol Myers Squibb in November 2020, Mr. Bauer served as the Chief Business Officer of MyoKardia, Inc., a clinical stage biopharmaceutical company,

Frank Torti MD, MBA, is the Vant Chair and President at Roivant Sciences, Executive Chairman at Immunovant and Priovant, and was the founding CEO and Chairman of Telavant from the time of its inception until its sale to Roche for $7.25B.

Eric Venker, MD, PharmD, serves as Chief Executive Officer of Immunovant and has been on its Board of Directors since 2020. He also leads Roivant Sciences as President, a role he has held since 2018, and previously held positions at Roivant, including Chief Medical Officer and Chief of Staff to the CEO.

The company develops anti-FcRn therapies to address the diverse needs of people with autoimmune diseases.

Immunovant, Inc. focuses on anti-FcRn technology to create targeted treatments for autoimmune diseases.

The company offers a contact form for inquiries.

Immunovant provides investor relations contact via email at info@immunovant.com.

Immunovant provides a confidential reporting method for concerns about violations of its Code of Business Conduct, policies, or laws.